Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
41
BSX Quote, Financials, Valuation and Earnings
Last price:
$74.13
Seasonality move
:
5.45%
Day range:
$73.16 - $75.29
52-week range:
$72.69 - $109.50
Dividend yield:
0%
P/E ratio:
38.22x
P/S ratio:
5.52x
P/B ratio:
4.70x
Volume:
16.9M
Avg. volume:
17.2M
1-year change:
-29.92%
Market cap:
$109.9B
Revenue:
$20.1B
EPS (TTM):
$1.94
Analysts' Opinion
-
Consensus RatingBoston Scientific Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 26 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $106.78, Boston Scientific Corp. has an estimated upside of 44.07% from its current price of $74.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $90.00 representing -21.43% downside risk from its current price of $74.12.
Fair Value
-
According to the consensus of 26 analysts, Boston Scientific Corp. has 44.07% upside to fair value with a price target of $106.78 per share.
BSX vs. S&P 500
-
Over the past 5 trading days, Boston Scientific Corp. has underperformed the S&P 500 by -3.14% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Boston Scientific Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Boston Scientific Corp. has grown year-over-year revenues for 20 quarters straight. In the most recent quarter Boston Scientific Corp. reported revenues of $5.3B.
Earnings Growth
-
Boston Scientific Corp. has grown year-over-year earnings for 5 quarters straight. In the most recent quarter Boston Scientific Corp. reported earnings per share of $0.45.
Enterprise value:
120.8B
EV / Invested capital:
--
Price / LTM sales:
5.52x
EV / EBIT:
30.98x
EV / Revenue:
6.02x
PEG ratio (5yr expected):
0.69x
EV / Free cash flow:
31.60x
Price / Operating cash flow:
35.77x
Enterprise value / EBITDA:
25.18x
Gross Profit (TTM):
$13.1B
Return On Assets:
7.06%
Net Income Margin (TTM):
14.41%
Return On Equity:
12.46%
Return On Invested Capital:
8.4%
Operating Margin:
19.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $14.2B | $16.7B | $20.1B | $4.6B | $5.3B | |
| Gross Profit | $8.8B | $10.3B | $13.1B | $2.7B | $3.7B | |
| Operating Income | $2.2B | $2.7B | $3.9B | $589M | $1B | |
| EBITDA | $3.4B | $3.9B | -- | $937M | -- | |
| Diluted EPS | $1.07 | $1.25 | $1.94 | $0.38 | $0.45 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.3B | $5.8B | $6.5B | $6.9B | -- | |
| Total Assets | $32.2B | $32.5B | $35.1B | $39.4B | -- | |
| Current Liabilities | $4.3B | $3.8B | $4.9B | $6.4B | -- | |
| Total Liabilities | $15.6B | $14.9B | $15.6B | $17.4B | -- | |
| Total Equity | $16.6B | $17.6B | $19.5B | $22B | -- | |
| Total Debt | $9.5B | $9.3B | $9.5B | $11.1B | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.4B | $2.9B | $4.6B | $1B | $1.3B | |
| Cash From Investing | -$1.7B | -$3B | -$5.8B | -$1.4B | -$502M | |
| Cash From Financing | -$9M | $1.6B | $3M | $7M | -$104M | |
| Free Cash Flow | $1.7B | $2.2B | $3.8B | $823M | $1.2B | |
BSX
Sector
Market Cap
$109.9B
$23.4M
Price % of 52-Week High
67.69%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
1.41%
-1.64%
1-Year Price Total Return
-29.92%
-21.81%
Beta (5-Year)
0.666
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$77.12
200-day SMA
Sell
Level
$99.68
Bollinger Bands (100)
Sell
Level
88.94 - 101.96
Chaikin Money Flow
Buy
Level
1.2B
20-day SMA
Sell
Level
$86.02
Relative Strength Index (RSI14)
Sell
Level
24.09
ADX Line
Sell
Level
33.98
Williams %R
Buy
Level
-93.5177
50-day SMA
Sell
Level
$91.72
MACD (12, 26)
Sell
Level
-5.52
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
882.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.3004)
Buy
CA Score
(Annual)
Level (0.2629)
Buy
Beneish M-Score
(Annual)
Level (-2.517)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-1.6971)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.
Stock Forecast FAQ
In the current month, BSX has received 26 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BSX average analyst price target in the past 3 months is $106.78.
-
Where Will Boston Scientific Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Boston Scientific Corp. share price will rise to $106.78 per share over the next 12 months.
-
What Do Analysts Say About Boston Scientific Corp.?
Analysts are divided on their view about Boston Scientific Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Boston Scientific Corp. is a Sell and believe this share price will drop from its current level to $90.00.
-
What Is Boston Scientific Corp.'s Price Target?
The price target for Boston Scientific Corp. over the next 1-year time period is forecast to be $106.78 according to 26 Wall Street analysts, 26 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BSX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Boston Scientific Corp. is a Buy. 26 of 26 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BSX?
You can purchase shares of Boston Scientific Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Boston Scientific Corp. shares.
-
What Is The Boston Scientific Corp. Share Price Today?
Boston Scientific Corp. was last trading at $74.13 per share. This represents the most recent stock quote for Boston Scientific Corp.. Yesterday, Boston Scientific Corp. closed at $74.12 per share.
-
How To Buy Boston Scientific Corp. Stock Online?
In order to purchase Boston Scientific Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BSX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BSX
Sector
P/E ratio
38.22x
23.34x
PEG ratio
0.69x
-0.01x
P/B ratio
4.70x
1.72x
Price / LTM sales
5.52x
1.51x
Growth Metrics
BSX
Sector
Revenue growth
15.9%
3.21%
Earnings growth
18.3%
10.12%
Revenue (5-year growth)
15.16%
6.27%
Earnings forecast
$0.78
-$0.19
Profitability
BSX
Sector
Profitability FY 2025
$13.9B
$2.7M
Return on invested capital
8.4%
-33.62%
Return on assets
7.06%
-29.68%
Return on equity
12.46%
-38.89%
Earnings Date
Last Earnings Date
Feb
4
Next Earnings Date
Apr
22
Estimated Next Earnings Date
May
6
Balance Sheet
BSX
Sector
Total cash
$1.4B
$25M
Short term investments
--
$23.9M
Total assets
$39.4B
$72.8M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
66
DIOD alert for Feb 13
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
